CANTON, Mass., March 17, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. today announced a poster presentation of the Company's completed Phase III clinical trial that evaluated the efficacy and safety of its lead drug candidate, Xtampza ER™, an abuse-deterrent, extended-release analgesic for chronic pain. The poster will be presented at the American Academy of Pain Medicine's (AAPM) 31st Annual Meeting, being held on March 19-22, 2015 at the Gaylord National Resort and Convention Center, National Harbor, Maryland.
Collegium will present the objectives, methods, and results of its Phase III clinical trial evaluating the analgesic efficacy of Xtampza ER, as compared with placebo in opioid-experienced and opioid-naïve subjects with moderate-to-severe chronic low back pain.
The Collegium poster will be presented on Friday and Saturday, March 20th and 21st, respectively.
Title: Safety and Efficacy of Oxycodone DETERx: An Extended-release, Abuse-deterrent Formulation in the Treatment of Moderate-to-severe Chronic Low Back Pain
Poster #: 226
Presenting Author: Ernest A. Kopecky, Ph.D., M.B.A., Vice President, Clinical Development, Collegium Pharmaceutical, Inc.
Date and Time: Friday, March 20th, 2015, 6 pm – 7:30 pm ET and Saturday, March 21st, 2015, 9:30 – 10:45 am ET
Session: AAPM 31st Annual Meeting Welcome Reception – Exhibits & Poster Sessions – Group 2
Location: Resource Center – Gaylord National Resort and Convention Center
CONTACT: Douglas R. Carlson Vice President, Corporate Development Collegium Pharmaceutical, Inc. 781-713-3739 email@example.com
Source:Collegium Pharmaceutical, Inc.